280 related articles for article (PubMed ID: 23035648)
21. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
[TBL] [Abstract][Full Text] [Related]
22. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.
Thepot S; Zhou J; Perrot A; Robin M; Xhaard A; de Latour RP; Ades L; Ribaud P; Petropoulou AD; Porcher R; Socié G
Leukemia; 2010 Nov; 24(11):1852-8. PubMed ID: 20827288
[TBL] [Abstract][Full Text] [Related]
23. Evolving concepts in prognostic scoring of chronic GvHD.
Lazaryan A; Arora M
Bone Marrow Transplant; 2017 Oct; 52(10):1361-1366. PubMed ID: 28346419
[TBL] [Abstract][Full Text] [Related]
24. Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP).
Jagasia MH; Savani BN; Stricklin G; Engelhardt B; Kassim A; Dixon S; Chen H; Chinratanalab W; Goodman S; Greer JP; Schuening F
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1288-95. PubMed ID: 19747637
[TBL] [Abstract][Full Text] [Related]
25. National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.
Lawitschka A; Gueclue ED; Januszko A; Körmöczi U; Rottal A; Fritsch G; Bauer D; Peters C; Greinix HT; Pickl WF; Kuzmina Z
Front Immunol; 2019; 10():1879. PubMed ID: 31507582
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
27. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
28. Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation.
Lertkovit O; Anurathapan U; Hongeng S; Thokanit NS; Pakakasama S
Int J Hematol; 2021 Apr; 113(4):556-565. PubMed ID: 33385291
[TBL] [Abstract][Full Text] [Related]
29. [Impact of chronic graft-versus-host disease on long-term outcome after allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia].
Wojnar J; Giebel S; Hołowiecka-Goral A; Krawczyk-Kuliś M; Markiewicz M; Stella-Hołowiecka B; Wylezoł I
Pol Arch Med Wewn; 2006 Jul; 116(1):671-7. PubMed ID: 17340974
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of prognostic factors among patients with chronic graft-versus-host disease.
Pérez-Simón JA; Afram G; Martino R; Piñana JL; Caballero-Velazquez T; Ringden O; Valcarcel D; Caballero D; Remberger M; de Paz Y; Sierra J; Miguel JS; Hagglund H
Haematologica; 2012 Aug; 97(8):1187-95. PubMed ID: 22371184
[TBL] [Abstract][Full Text] [Related]
31. Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.
Chen CT; Liu CY; Yu YB; Liu CJ; Hsiao LT; Gau JP; Chiou TJ; Liu JH; Liu YC
PLoS One; 2017; 12(9):e0185210. PubMed ID: 28934311
[TBL] [Abstract][Full Text] [Related]
32. Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD.
Gorfinkel L; Raghunandan S; Watkins B; Hebert K; Neuberg DS; Bratrude B; Betz K; Yu A; Choi SW; Davis J; Duncan C; Giller R; Grimley M; Harris AC; Jacobsohn D; Lalefar N; Farhadfar N; Pulsipher MA; Shenoy S; Petrovic A; Schultz KR; Yanik GA; Blazar BR; Horan JT; Langston A; Kean LS; Qayed M
Bone Marrow Transplant; 2024 May; 59(5):680-687. PubMed ID: 38383714
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
[TBL] [Abstract][Full Text] [Related]
34. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.
DeFilipp Z; Alousi AM; Pidala JA; Carpenter PA; Onstad LE; Arai S; Arora M; Cutler CS; Flowers MED; Kitko CL; Chen GL; Lee SJ; Hamilton BK
Blood Adv; 2021 Oct; 5(20):4278-4284. PubMed ID: 34521116
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for the development of ocular graft-versus-host disease (GVHD) dry eye syndrome in patients with chronic GVHD.
Wang JC; Teichman JC; Mustafa M; O'Donnell H; Broady R; Yeung SN
Br J Ophthalmol; 2015 Nov; 99(11):1514-8. PubMed ID: 25947556
[TBL] [Abstract][Full Text] [Related]
36. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
37. Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes.
Novitzky-Basso I; AlHayli S; Shin E; Pasic I; Al-Shaibani Z; Lam W; Law A; Michelis FV; Gerbitz A; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Eur J Haematol; 2021 Apr; 106(4):508-519. PubMed ID: 33421199
[TBL] [Abstract][Full Text] [Related]
38. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
39. Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease.
El Jurdi N; Herzog S; Shanley R; Holtan SG; MacMillan ML; Weisdorf DJ
Transplant Cell Ther; 2024 Jun; 30(6):616-625. PubMed ID: 38479549
[TBL] [Abstract][Full Text] [Related]
40. Chronic cutaneous graft-versus-host disease in children: A report of 14 patients from a tertiary care pediatric dermatology clinic.
Nanda A; Husain MAA; Al-Herz W; Almekaimi A; Al-Sabah H; Al-Otaibi M
Pediatr Dermatol; 2018 May; 35(3):343-353. PubMed ID: 29536565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
